Important Abstracts in HER2-positive Breast Cancer From SABCS 2023.

Published Date: 06 Jan 2024

Data from the HER2CLIMB-02 trial of tucatinib plus T-DM1 and a 9-year follow-up of the KATHERINE trial, as discussed by Dr. Harold Burstein, are highlights in HER2+ breast cancer from SABCS 2023.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot